The global anti-viral drugs market is expected to be valued at US$ 59,596.8 Million in 2022. The induction of the generic version of antiviral medicines and rising awareness about the availability of various vaccines for viral infections is affecting the growth throughout the forecast period. The overall demand for Anti-Viral Drugs is projected to grow at a CAGR of 3.9% between 2022 and 2032, totaling around US$ 87,675.36 Million by 2032.
Anti-viral drugs are medicines which are used specially for treating viral infections. Most anti-viral drugs are used for particular viral infections, similar to antibiotics, while a broad-spectrum anti-viral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen, instead they inhibit the development of those viruses.
The global anti-viral drugs market is projected to register a moderate growth rate in the pharmaceutical market and which is anticipated to increase due to rise in awareness level, increase in the diseased population and introduction of new drugs with improved efficacy.
Some major patents are reaching their expiry during forecast period, such as for Combivir, Sustiva, Tenofovir, Tamiflu, Relenza and Telbivudine. The patent expiries of these blockbuster drugs is expected to trigger generic competition in the antivirals therapeutics market, which will make the market more competitive.
The late stage pipeline drugs are expected to enter the market, which will positively impact the market. Most antivirals are considered comparatively harmless to host, and therefore are used to treat infections. They are different from viricides, which are not used for medication but can destroy or deactivate virus particles, either outside or inside the body.
The anti-viral drugs are used in the treatment of patients suffering from herpes viruses, HIV, influenza A and B viruses and the hepatitis B and C viruses.
Request Sample Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1951
Anti-viral Drugs Market: Drivers and Restraints
As of October 2013, according to WHO, there were around 35.3 Mn people globally, infected with HIV. Therefore, increased viral infection incidences is one of the important factors that drives the anti-viral drugs market growth. Because of the solid R&D activities, newer and advanced treatments and formulations, such as vaccines, combination therapy and others, are being introduced in the market.
Hence, strong R&D is one of the crucial factors in the anti-viral drugs market growth. On the other hand, high risk of failure, high cost of R&D and therapy, and government austerity are some of threats expected to hinder the growth of market.
These are some factors anticipated to fuel growth of global anti-viral drugs market within the forecast period of 2016-2026. However, increasing usage of natural products and high cost of developing drugs are the key challenges faced by the market.
Anti-viral Drugs Market: Overview
The generic market of anti-viral drugs is presently dominated by products such as didanosine, zidovudine, lamivudine and stavudine. The biggest driver of overall anti-viral drugs market is Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for more than half the share of the market 2010.
At the end of 2012, 9.7 million people in low-income and middle-income countries were on antiretroviral treatment (ART). According to WHO, in 2012, number of patients on ART increased by 1.6 Mn, the largest increase in one year.
Nearly four out of five people were freshly put on treatment in the sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants.
Ask For Customization:
https://www.futuremarketinsights.com/customization-available/rep-gb-1951
Anti-viral Drugs Market: Regional Overview
Region wise, the global anti-viral drugs market is classified into regions namely, North America, Eastern Europe, Western Europe, Latin America, Japan, Asia-Pacific, Middle East and Africa. According to WHO, in countries with Major ART scale-up such as Brazil or China, the death rate among people living with HIV has decreased by 80%. In 2015, in India the number of people living with HIV were 2.1 Mn and in U.S. the number was around 1.2 Mn in the year 2013.
Anti-viral Drugs Market: Key Players
Some of the key players in global anti-viral drugs market, which are focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.
Key Segments Covered in the Anti-Viral Drugs Industry Analysis
Anti-Viral Drugs Market by Product type:
- Hepatitis-C antivirals
- HIV antivirals
- Herpes antivirals
- Hepatitis-B antivirals
- Influenza antivirals
- Others (Pneumonia, Flu, etc.)
Anti-Viral Drugs Market by End-user:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
Anti-Viral Drugs Market by Region:
- North America Anti-Viral Drugs Market
- Latin America Anti-Viral Drugs Market
- Europe Anti-Viral Drugs Market
- Asia Pacific Anti-Viral Drugs Market
- The Middle East & Africa Anti-Viral Drugs Market
Get In Touch With Our Team For 20% Flat Discount:
https://www.futuremarketinsights.com/ask-question/rep-gb-1951
Have a Look at More Valuable Insights of Healthcare
Drug Delivery Technology Market Size is expected to be valued at US$ 39,330 Million in 2022. Increasing adoption of advanced technology for effectively delivering the drug to the target site is expected to drive overall market growth.
Drug of Abuse Testing Market Share is projected to reach a valuation of US$ 1.5 Bn in 2021, with sales growing at above 5% CAGR through 2031
Drug Designing Tools Market Demand is expected to be worth around US$ 5.15 Bn by 2028, up from US$ 2.87 Bn in 2022, rising at a CAGR of 8.7% from 2022 to 2028
ABOUT FUTURE MARKET INSIGHTS, INC.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
Enquiries: sales@futuremarketinsights.com
The post Anti-Viral Drugs Market to be worth USD 87,675.36 Million by 2032 | CAGR of 3.9% appeared first on Future Market Insights.
Published by: Future Market Insights, Inc.